Cargando...

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone

Multiple myeloma is a common plasma cell malignancy with a median overall survival of fewer than 10 years. Proteasome inhibitors comprise an important part of the treatment regimen for this disease. The present study reports the case of a 57-year-old man who experienced a second relapse of multiple...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:World J Oncol
Autores principales: Erath, Alexandra, Patel, Dilan A., Hosack, Eric A., Patanella, James E., Ibach, Daniel M., Kassim, Adetola A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Elmer Press 2020
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7011904/
https://ncbi.nlm.nih.gov/pubmed/32095187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/wjon1241
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!